Home » Networking, Picture Gallery » MMRGlobal Announces Final Settlement Conference and Jury Trial Dates in MyMedicalRecords Patent Litigation

MMRGlobal Announces Final Settlement Conference and Jury Trial Dates in MyMedicalRecords Patent Litigation

LOS ANGELES, CA — (Marketwired) — 09/22/14 — (OTCQB: MMRF), through its wholly owned subsidiary MyMedicalRecords, Inc. (collectively, “MMR”), announced today that a Post-Markman Scheduling Order was entered by the United States District Court, Central District of California on September 19, 2014 in plaintiff MyMedicalRecords patent infringement cases against defendants Quest Diagnostics, Inc., Jardogs, LLC, Allscripts Healthcare Solutions, Inc., and WebMD Health Corp. & WebMD Health Services Group, Inc. MyMedicalRecords is pleased that the Court denied Defendants– request to stay discovery and instead opened discovery through 2/18/2015, also setting a last date to conduct settlement conferences of 3/18/2015 and a Jury Trial starting 5/19/2015. A complete copy of the comprehensive scheduling order leading to trial can be found on PACER at .

The Company also commented that MMR shareholders can now look forward to obtaining a prompt determination on the merits of MMR–s patent claims through a jury trial.

John Fuisz, co-founder of The Fuisz-Kundu Group and an attorney for MyMedicalRecords, said, “MMR is pleased the Court denied Defendants– request to stay discovery and instead opened discovery and set a comprehensive schedule leading to a trial date. We look forward to taking discovery and getting to trial on the merits of MMR–s patent infringement claim.”

MyMedicalRecords, Inc. is a practicing entity and a leading provider of secure and easy-to-use Personal Health Records through its PHR, and MMRPro document management and imaging systems for . MMR also offers , which provides an online site to securely store important legal, financial, insurance and other important documents, as well as medical and personal health information. MMR currently has 13 issued U.S. health IT patents including U.S. Patent Nos. 8,301,466; 8,352,287; 8,352,288; 8,121,855; 8,117,646; 8,117,045; 8,321,240; 8,498,883; 8,626,532, 8,645,161; 8,725,537; 8,768,725 and 8,775,212, as well as additional applications and continuation applications involving inventions pertaining to Personal Health Records, Patient Portals and other Electronic Health Record systems. The most recently issued patent, U.S. Patent No. 8,775,212, represents MMR–s first Clinical Trials patent and includes 18 claims directed to methods and systems that provide for self-reporting being used to create Electronic Health Records for purposes including Clinical Trials. In addition to the U.S., MMR currently has patents issued, pending and/or applied for in 11 other countries or regional authorities including Australia, Singapore, New Zealand, Mexico, Japan, Canada, Hong Kong, China, South Korea, Israel and Europe.

MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user–s account. MMR–s professional offering, , is designed to give physicians– offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients through an integrated patient portal. Through its merger with Favrille, Inc. in January 2009, MMR acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId/Specifid vaccine clinical trials for the treatment of B-Cell Non-Hodgkin–s lymphoma. To learn more about MMRGlobal, Inc. visit . View demos and video tutorials of MMR–s products and services at . Follow us at and .

All statements in this release that are not strictly historical facts are “forward-looking statements.” Such forward-looking statements are based on MMR–s current assumptions, beliefs and expectations, and involve risks, uncertainties and other factors that may cause MMR–s actual results to be materially different from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words such as “expect,” “plan,” “possibility,” “offer,” “if,” “negotiate,” “when,” “believe,” “will,” “estimate,” “continue,” and similar expressions. Risks, uncertainties, and other factors that could cause or contribute to such differences include, but are not limited to: ongoing and future intellectual property enforcement actions; the ability to successfully litigate or settle claims of patent infringement; MMR–s ability to develop, license and monetize its patents in the portfolio for both MMR–s health IT and biotechnology IP assets; reliance upon the successful operations of its business partners in selling MMR–s products and services, the timing of milestone payments in connection with licensing its IP; MMR–s ability to obtain necessary financing, generate sufficient cash flow, and maintain appropriate indebtedness; and the increasing development of market competition in the area of electronic records in clinical trials. These factors and others are described in more detail in MMR–s public filings with the Securities and Exchange Commission, including the risks discussed in the “Risk Factors” section in MMR–s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Copies of these reports can be found on MMR–s website () under the heading “Investor Relations.” MMR is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Michael Selsman
Public Communications Co.

(310) 922-7033

Posted by on 22. September 2014. Filed under Networking, Picture Gallery. You can follow any responses to this entry through the RSS 2.0. You can leave a response or trackback to this entry

You must be logged in to post a comment Login


Recent Comments

    © 2023 So-Co-IT. All Rights Reserved. Log in - Copyright by LayerMedia

    Blogverzeichnis - Blog Verzeichnis bloggerei.de Blog Top Liste - by TopBlogs.de Bloggeramt.de